CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Mechanical circulatory support devices in advanced heart failure: 2020 and beyond A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial Association Between Functional Impairment and Medication Burden in Adults with Heart Failure Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? The year in cardiology: heart failure: The year in cardiology 2019 Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Trial
|<<... 4 5 6 7 8 9 10 ...>>|

Review ArticleVolume 72, Issue 19, November 2018

JOURNAL：J Am Coll Cardiol. Article Link

Ejection Fraction Pros and Cons: JACC State-of-the-Art Review

TH Marwick Keywords: ejection fraction; heart failure; myocardial infarction; strain; valvular heart disease

ABSTRACT

Ejection fraction (EF) reflects both cardiac function and remodeling, and is widely recognized as a valuable diagnostic and prognostic tool. Its use in a variety of settings, ranging from heart failure and myocardial infarction to valvular heart disease, has made it a cornerstone of modern cardiology, pervading guidelines and practice. However, the development of the test was in another era, with younger patients and a lower prevalence of heart failure with preserved EF. The performance expectations of EF in the current era are also demanding-in relation to detection of subclinical LV dysfunction, and especially relating to recognition of changes in LV function on sequential testing-for example in patients taking cardiotoxic drugs. This review discusses whether the impressive evidence base for EF justifies its ongoing use in the context of newer markers of LV function, and the sophisticated questions posed by modern cardiology.



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top